HLRCC tumors have also been shown to demonstrate several markers of EMT including increased ZEB1 expression and downstream markers of ZEB1 upregulation, such as VIM, were upregulated in this cohort [52, 53]. This evidence concerns the gene ZEB1 and hereditary leiomyomatosis and renal cell cancer.